Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma

ISSN： 2190-393X

Source： Drug Delivery and Translational Research, Vol.1, Iss.4, 2011-08, pp. : 277-288

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

1,3-Selenazine derivatives induce cytotoxicity and DNA fragmentation in human HT-1080 fibrosarcoma cells

By Koketsu M. Ishihara H. Wu W. Murakami K. Saiki I.

European Journal of Pharmaceutical Sciences, Vol. 9, Iss. 2, 1999-12 ,pp. : 157-161

Elsevier

Access to resources Recommend Favorite

Cellular Delivery In Vivo of siRNA-Based Therapeutics

Current Pharmaceutical Design, Vol. 14, Iss. 34, 2008-12 ,pp. : 3603-3619

Bentham Science Publishers

Access to resources Recommend Favorite

Silibinin activated ROS-p38-NF-B positive feedback and induced autophagic death in human fibrosarcoma HT1080 cells

By Duan Wen-Jun

Journal of Asian Natural Products Research, Vol. 13, Iss. 1, 2011-01 ,pp. : 27-35

Taylor & Francis Ltd

Access to resources Recommend Favorite

Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy

Current Pharmaceutical Design, Vol. 21, Iss. 31, 2015-09 ,pp. : 4637-20

Bentham Science Publishers

Access to resources Recommend Favorite

MDM2 Oncogene as a Novel Target for Human Cancer Therapy

Current Pharmaceutical Design, Vol. 6, Iss. 4, 2000-03 ,pp. : 393-416

Bentham Science Publishers

Access to resources Recommend Favorite